Tempus announces the clinical launch of its immune profile score algorithmic test

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced the clinical launch of its immune profile score (ips) algorithmic test. ips, which is now available for clinicians to order, is a multimodal biomarker that can be used as a prognostic indicator for adult patients with stage iv and metastatic pan-solid tumors who are already considered candidates for immune checkpoint inhibitor (.
TEM Ratings Summary
TEM Quant Ranking